PT - JOURNAL ARTICLE AU - Eckhard Mayer AU - Andrea M. D'Armini AU - Hossein-Ardeschir Ghofrani AU - Ekkehard Grünig AU - Pavel Jansa AU - Nick H. Kim AU - Gerald Simonneau AU - Adam Torbicki AU - Chen Wang AU - Martin R. Wilkins AU - Neil Davie AU - Arno Fritsch AU - Marius M. Hoeper TI - Efficacy of riociguat in patients with inoperable CTEPH vs persistent/recurrent PH after pulmonary endarterectomy (PEA): Results from the phase III CHEST-1 study DP - 2013 Sep 01 TA - European Respiratory Journal PG - 1781 VI - 42 IP - Suppl 57 4099 - http://erj.ersjournals.com/content/42/Suppl_57/1781.short 4100 - http://erj.ersjournals.com/content/42/Suppl_57/1781.full SO - Eur Respir J2013 Sep 01; 42 AB - BackgroundIn CHEST-1, riociguat significantly improved several clinically relevant endpoints in CTEPH patients (pts).AimsHere we describe and compare its clinical effect in subgroups of pts with inoperable and persistent/recurrent CTEPH.MethodsPts (34% male, mean age 59 y) received placebo (pbo) or riociguat (up to 2.5 mg tid) for 16 wks. The primary endpoint was change in 6MWD; secondary endpoints were change in PVR, NT-proBNP, WHO functional class (FC), time to clinical worsening, Borg dyspnea score, and EQ-5D and Living with PH (LPH) questionnaires.ResultsAt baseline (BL), inoperable pts had lower 6MWD (341±80 vs 363±76 m) and higher PVR (861±452 vs 595±233 dyn·s·cm-5) and NT-proBNP (1732±2690 vs 1100±1150 pg/mL) vs persistent/recurrent pts. Selected endpoints and safety data are shown below.View this table:ConclusionsRiociguat improved primary and secondary endpoints in both pts with inoperable and pts with persistent/recurrent CTEPH vs BL, with a more marked effect in inoperable pts.